Telemedicine in India: What Works, What Does Not, and What Patients Actually Want

Telemedicine in India has generated considerable enthusiasm since 2020, but six years into its mainstream adoption, the evidence is more nuanced than its advocates admit. The technology works - the connectivity is there, the platforms are mature, the regulatory framework exists. What the technology cannot fix is a harder problem: patients still prefer in-person consultation for anything they regard as serious, and practitioners are often optimizing for the wrong use cases.

This article maps the telemedicine landscape as it actually exists in mid-2026: government scale (e-Sanjeevani has crossed 300 million consultations), private platform growth (Apollo 247, Practo, 1mg), and the independent practitioner's more difficult question of whether and how to build their own telehealth capability. We introduce the SCREEN Matrix - a practical fit tool that helps practitioners identify which consultation types belong online and which do not, and avoid the false efficiency of putting complex first-consultations behind a video call.

After reading this, you will understand where telemedicine creates genuine clinical and business value for Indian practitioners in 2026, which patient segments embrace it, what the regulatory picture actually requires, and how to avoid the two most common strategic mistakes: over-extending telehealth into inappropriate clinical use cases, and under-investing in it for the use cases where it clearly wins.

---

Dr. Priya Nair runs a general medicine clinic in Indiranagar, Bengaluru. In 2021, she set up a telehealth consultation service on Practo - her first pandemic-era experiment. By late 2021, she was doing forty online consultations a week. By 2023, she had cut that to fifteen. By early 2025, she had shut the Practo channel entirely and built her own WhatsApp-based video call workflow for existing patients only. Her reason: "I kept getting patients who needed to be in front of me, but they thought a video call was the same thing. And I couldn't charge what I needed to charge because they compared me to the ₹200 consultation on the platform."

Dr. Nair's experience is not unusual. It captures a fundamental mismatch that the telemedicine industry has not honestly reckoned with: the use cases that generate volume for platforms are not always the use cases where telemedicine actually works. Patients shopping for cheap, fast consultations are not the same as patients seeking ongoing chronic disease management or post-discharge follow-up. When practitioners conflate the two, they end up with platforms that attract the first group while frustrating the second - and in the process, erode their own fee structures and clinical satisfaction.

The scale numbers are real. E-Sanjeevani, the government's AB-HWC telemedicine platform, crossed 300 million consultations by 2026 - a public health achievement with few global parallels. Apollo 247 and 1mg have grown their teleconsultation user bases significantly. Practo continues to be the dominant platform for urban outpatient discovery. By 2024, India had crossed 800 million smartphone users, with a median population age of 29 - the demographic profile of a country with high appetite for digital services. On paper, telemedicine should be thriving uniformly.

The reality is more segmented. E-Sanjeevani succeeds because it is embedded in an existing public health infrastructure for specific, high-volume use cases: maternal and child health, non-communicable disease management, specialist access from rural health and wellness centres. It is not a general-purpose consultation service - it is a referral pathway with clinical protocols behind it. Private platforms succeed for triage, quick script renewals, and patients comfortable managing their own minor complaints. What both struggle to serve reliably is the middle tier: the patient with a complex, evolving complaint who prefers a familiar doctor and does not want to explain their history from scratch on every call.

The independent practitioner sits at that junction. Neither the public platform model nor the private marketplace model is designed for what they actually offer - continuity, relationship, and clinical judgment built over time. Building telemedicine that captures the real value of that relationship requires a different architecture than the platforms provide. That architecture starts with an honest assessment of which consultations belong online and which do not.

---

India's telemedicine opportunity is shaped by factors that make both the promise and the constraints different from the US or European models that most research cites. The smartphone penetration milestone of 800 million users (2024) matters not because it creates demand uniformly, but because it creates differentiated demand: urban middle-class patients who expect digital convenience; tier-2 and tier-3 town patients for whom a smartphone video call is genuinely their only specialist access option; and rural patients served by community health workers using government platforms on their behalf. These three populations have different needs, different willingness to pay, and different threshold conditions for trusting a screen over a doctor's room.

The regulatory architecture has been clarified without being fully resolved. The Telemedicine Practice Guidelines issued originally by the Medical Council of India (now the National Medical Commission, NMC) in 2020 were a landmark - they legitimised the practice and provided a framework for prescription, record-keeping, and scope of service. But the NMC's guidelines on advertising and professional conduct still create ambiguity for practitioners building their own patient-facing digital presence. Promoting clinical services online invites scrutiny under rules written before digital channels existed in their current form. The Digital Personal Data Protection Act (DPDPA) 2023 adds a separate and significant layer: any practitioner collecting, storing, or processing patient health information electronically now has statutory obligations around consent, storage limitation, and data breach notification. Most independent practitioners are not yet DPDPA-compliant. This is not a future risk - it is a current one.

The Ayushman Bharat Digital Mission (ABDM) and the ABHA health ID framework represent a longer-term structural shift that most independent practitioners are underweighting. When ABHA adoption reaches critical mass, practitioners who have already built digital workflows will find it significantly easier to integrate with the national health stack - pulling patient records, sharing prescriptions electronically, and connecting to the e-Sanjeevani referral network. Sharma et al. (2025), a peer-reviewed study of 5,061 PM-JAY eligible individuals across seven Indian states published in Global Health Action (PMC11998304), found that 48.0% used private outpatient care, 18.3% used public facilities, and 23.1% reported no regular outpatient care at all. That 23.1% with no regular access represents a population that telemedicine, if correctly designed, could genuinely serve - but it is a population with limited ability to pay and limited digital health literacy, which private platforms do not prioritise.

Cultural factors matter in ways that adoption statistics obscure. Indian patients - particularly for serious or stigmatised conditions including oncology, psychiatry, sexual health, and complex endocrine complications - often prefer consultation with a trusted, known doctor over a video screen, regardless of digital access. The FICCI-EY Parthenon industry survey (October 2025) of 1,000+ patients found that patients rely heavily on "informal proxies like brand reputation and word-of-mouth" when choosing healthcare providers. That trust dynamic does not transfer automatically to a new video consultation service. It must be earned, transferred, and maintained - which requires a different approach to telemedicine onboarding than simply opening a booking slot on a platform.

---

The most methodologically robust Indian primary care utilisation data available as of July 2026 is Sharma et al. (2025), published in Global Health Action (PMC11998304). The cross-sectional study surveyed 5,061 PM-JAY eligible individuals across seven states, using a structured household interview methodology, and documented that nearly a quarter (23.1%) had no regular outpatient care. The study's limitation is population scope: PM-JAY eligible individuals represent the lower-income insured segment, not the urban middle class that most private telemedicine platforms target. The finding is nonetheless instructive - telemedicine advocacy that assumes universal digital access as the primary barrier misses that significant proportions of India's patient population lack consistent care of any kind, digital or otherwise. Closing an access gap requires knowing what kind of gap it is.

E-Sanjeevani's publicly reported consultation milestones constitute operational evidence, not peer-reviewed research - that distinction matters for how the numbers should be interpreted. The platform's claimed 300 million+ cumulative consultations by 2026 is a utilisation figure. It tells us that government-backed, zero-cost, workflow-integrated telemedicine at scale is feasible in India. It tells us less about outcomes, quality, or what proportion of consultations resulted in appropriate clinical resolution versus safe referrals. The Ministry of Health and Family Welfare's monitoring frameworks focus on access metrics; outcome data remains sparse in the public domain. Platform scale and clinical effectiveness are not the same measurement.

A 2023 systematic review published in the Journal of Medical Internet Research examining telemedicine adoption in low- and middle-income countries found that teleconsultation for chronic disease management - hypertension, diabetes, mental health - showed consistent positive effects on treatment adherence when combined with structured follow-up protocols. This is directionally applicable to India, though the included studies skew toward sub-Saharan Africa and South-East Asia rather than South Asian contexts specifically. The key finding: telemedicine improves chronic disease outcomes when it is designed as a care management system, not a one-off consultation service. This distinction - system versus transaction - is central to how independent Indian practitioners should think about telemedicine investment.

The FICCI-EY Parthenon industry survey (October 2025), which is an industry report rather than peer-reviewed research, surveyed 1,000+ patients and 100+ clinicians. The headline finding that 83% of patients aspire to accessible health information is a stated preference rather than a behavioral measure - the report itself acknowledges this gap between aspiration and actual health-seeking behavior. More analytically useful is the finding on trust proxies: patients rely on informal brand reputation and word-of-mouth rather than formal quality indicators when choosing providers. This is consistent with the established literature on trust in healthcare decision-making and has direct implications for how telemedicine services should be positioned. A video consultation service without an established reputation baseline will not attract the patients who most benefit from continuity care.

Mental health teleconsultation has the strongest international evidence base for telemedicine efficacy. A 2022 meta-analysis in Lancet Psychiatry found no significant difference in therapeutic outcomes between in-person and video-based cognitive behavioral therapy for anxiety and depression among established patients. This is directionally applicable to India. In an Indian context, the implication matters enormously: the National Mental Health Survey 2015-16 estimated a treatment gap of 73-86% for common mental disorders, and stigma creates a genuine preference among some patients for the privacy of a remote consultation. Psychiatrists and clinical psychologists who dismiss telemedicine as an inferior modality are dismissing evidence that contradicts their position for specific, well-characterised use cases.

Teledermatology - asynchronous, store-and-forward image-based triage in particular - has been validated in multiple international settings for accurately ruling out serious diagnoses and appropriately prioritising in-person evaluation. Indian platforms including 1mg have built dermatology consultation workflows; independent dermatologists who have experimented with image-first triage before video consultation report improvement in consultation efficiency and patient preparation. The limitation in the published Indian evidence is methodological: most Indian teledermatology data is single-site or single-platform, which limits generalisability. The directional finding - that photograph-based triage is accurate enough to be clinically useful for common dermatological complaints - holds across jurisdictions.

---

The following section is Influx Health's interpretation and opinion, not research.

Working with 60+ Indian healthcare organizations over three years, we have observed a consistent pattern: the practitioners who get the most value from telemedicine are almost never the ones who started it most enthusiastically. The early adopters who launched platforms in 2020-21, often under lockdown pressure, built their workflows around the emergency - high volume, low selectivity, any channel that kept revenue flowing. Many found themselves with services that attracted the wrong patient type at the wrong consultation stage, eroded their average consultation fee, and added administrative overhead without proportional clinical or revenue reward. The practitioners who are genuinely winning with telemedicine in 2026 are typically those who came to it deliberately, usually two or three years after the first wave, with a specific use case in mind and a clear sense of which patients they were designing for.

What the research does not capture well is the consultation quality problem. In our direct experience, the first consultation for an undifferentiated complaint - fatigue, weight change, a lump a patient has been worried about for six months - is almost uniformly better done in person. Not because the technology fails, but because the clinical interview for undifferentiated symptoms depends on observation, proximity, and the thousand small signals that a physical consultation enables and a video call does not. Patients often book telemedicine for first consultations because it is convenient; practitioners accept them because volume is reassuring. The clinical outcome risk of that pattern is real. The practitioners we work with who have the strongest clinical reputations are also the ones most insistent on this boundary.

The business model tension is worth naming directly. Platforms like Practo and Apollo 247 monetise through volume - their economic incentive is to drive consultation throughput at accessible price points. The independent practitioner's economic incentive is the opposite: fewer, deeper, higher-value relationships. These are not the same business model dressed in digital clothing. An independent specialist who builds telemedicine as an extension of existing patient relationships - follow-up appointments, monitoring sessions, quick checks for established patients - will generate better economics than one who uses a platform to acquire new patients at platform-set fees. The first model strengthens the practice; the second frequently subsidizes the platform's growth at the practitioner's expense. This is not a criticism of platforms. It is a clarification that they are designed to serve different strategic goals than those of most independent practitioners.

One observation we find consistently underappreciated: WhatsApp is Indian telemedicine's dark matter. Enormous volumes of clinical communication, prescription sharing, follow-up advice, and informal second opinion happen daily over WhatsApp - none of it regulated, none of it captured in platform statistics, and much of it clinically reasonable by the standards of the consultation it represents. This is not a compliance recommendation; the DPDPA and NMC guidelines create real risks for unstructured WhatsApp clinical communication, and practitioners should take those risks seriously. It is an observation that the official telemedicine ecosystem numbers dramatically undercount the actual digital clinical interaction volume in India. Any practitioner building a formal telemedicine service should account for the informal parallel channel that already exists among their patient base, and think carefully about how to bring it into a more structured, compliant workflow rather than simply adding a new layer on top.

---

A fit matrix for telemedicine consultation decisions

Practitioners frequently ask a binary question: "Should I do telemedicine?" The more useful question is: "Which consultations belong on screen, and which must stay in person?" The SCREEN Matrix provides a structured answer, based on six fit criteria. When a consultation matches most or all criteria, telemedicine is appropriate. When it matches few or none, in-person is the right channel - regardless of patient preference or logistical convenience.

S - Sustained Relationship (Existing Patient, Known Case) Telemedicine works best with patients you already know. If you have examined the patient in person, reviewed their history, and established a diagnosis, a follow-up video call allows you to monitor progress without duplicating the diagnostic work the in-person consultation already did. A returning hypertension patient checking in after a medication adjustment is a strong fit. A new patient with a two-week history of fatigue and unintentional weight loss is not - regardless of how far they live from your clinic. The first consultation for a serious, complex, or undifferentiated complaint almost always requires physical examination. "First meeting via video" is a weak-fit scenario by default; treat exceptions as requiring explicit clinical justification.

C - Chronic Condition Management Hypertension check-ins, diabetes review, thyroid monitoring, asthma control assessment, post-cardiac event follow-up - these are the use cases where telemedicine delivers genuine, evidence-supported clinical value. The diagnostic parameters are established, the patient understands their condition, and the clinical question is specific: are the numbers where they need to be, and does the current management plan need adjusting? This is efficient, clinically appropriate, and patients generally appreciate not travelling for a fifteen-minute structured review. Chronic disease management is the single largest telemedicine opportunity for independent internal medicine, endocrinology, and cardiology practices in India. Most are significantly under-exploiting it.

R - Reviewable Without Physical Examination Some clinical questions can be fully addressed with what a camera, a microphone, and a structured patient report can provide. Dermatology is the clearest example: photograph-based triage for rashes, lesions, wound review, and post-procedure healing assessment is validated as accurate for common presentations. Psychiatry and psychology are another: the therapeutic relationship, talk-based assessment, and symptom monitoring for established mental health patients do not require physical proximity. Post-operative check-ins for uncomplicated recoveries, spectacle prescription queries in ophthalmology, and follow-up for patients with stable infectious disease on long-term prophylaxis are further examples. The honest test is clinical: can you reach a sound conclusion without palpation, auscultation, range-of-motion assessment, or other examination findings? If yes, the consultation is reviewable remotely. If the clinical answer depends on examination, it is not.

E - Established Prescription Renewal Repeat prescription issuance for stable, long-term patients on medications they have been using safely is one of the clearest strong-fit telemedicine use cases in the Indian regulatory context. The clinical risk is low for a stable patient on a known drug with a documented response history; the patient convenience gain is high; and the NMC telemedicine guidelines permit prescription issuance following teleconsultation with appropriate record-keeping. The important caveats: this is not appropriate for new medications, for drugs with narrow therapeutic windows where current blood work is needed to confirm safe continuation, or for controlled substances without a clear and current clinical record. Practitioners who have built efficient teleconsultation workflows for repeat prescriptions - combining a brief structured check-in with electronic record update - report it is among the highest-value use cases for patient retention and practice efficiency.

E - Emotional and Mental Health Consultations Psychiatry and clinical psychology represent telemedicine's strongest evidence case for equivalence with in-person care among established patients. The Lancet Psychiatry meta-analysis (2022) finding of no significant outcome difference for video-based versus in-person CBT is among the more robust findings in the telemedicine literature (directionally applicable to India). Critically, for many patients managing mental health conditions, the privacy of a video call from home is not a second-best option - it is actively preferred because it removes the social visibility of entering a mental health facility. In a country with documented treatment gaps of 73-86% for common mental disorders, independent psychiatrists and clinical psychologists who have not built telehealth into their practice are leaving a genuine access and clinical gap unfilled. The combination of strong evidence, high treatment gap, and patient preference for privacy makes this the most clear-cut telemedicine build recommendation in this article.

N - Navigation, Triage, and Non-Emergency Assessment Using telemedicine as a triage and navigation layer - is this something that needs to be seen today, or can it wait a week; should this patient go to an emergency department or a specialist clinic; does this symptom pattern warrant urgent investigation - is underused and undervalued by independent practitioners. A five-to-ten minute video or even a structured asynchronous message exchange can triage out unnecessary emergency visits, guide patients to the appropriate level of care, and build substantial patient loyalty at low consultation cost. This is not primarily a revenue play; it is a relationship play that reduces no-shows, prevents unnecessary emergency department utilisation, and positions the practitioner as the patient's first call when something worrying happens. Practitioners who have built this function report that it is one of the strongest patient retention mechanisms in their practice.

Where the SCREEN Matrix signals Weak Fit: any first consultation for an undifferentiated or potentially serious complaint; any consultation where physical examination is the diagnostic instrument; emergency presentations; procedures; new mental health assessments for patients with significant risk history; and any situation where the patient has expressed discomfort with video as a modality. Respecting weak-fit signals is not a failure of telemedicine strategy - it is good clinical judgment, and patients notice the difference.

---

• Audit your last 100 appointment records against the SCREEN Matrix this week. Identify consultations that were conducted in-person but match strong-fit criteria - these are telemedicine opportunities you are not capturing. Identify the inverse: video consultations that in hindsight needed physical examination. This diagnostic takes approximately two hours and will clarify your telemedicine strategy faster than any market research or platform comparison exercise.

• Engage a legal professional to review your DPDPA compliance before extending any digital patient data collection. If you are collecting names, phone numbers, health complaints, or prescription information through any digital channel - including WhatsApp, booking forms, or patient management software - you have current obligations under the Digital Personal Data Protection Act 2023. A patient consent notice and data processing terms document is the minimum starting point.

• Design your telemedicine service for existing patients first, new patient acquisition second. Contact your 40-50 most frequent returning patients with an offer for follow-up or chronic disease management via video consultation. This tests your workflow, generates revenue from a known base, and identifies friction points before you open the service to unfamiliar patients. Most practitioners find this cohort converts at significantly higher rates than platform-acquired users.

• Set a distinct and defensible fee for telemedicine consultations - and hold it. Do not default to your in-person rate or to the platform market rate. Calculate the actual value exchange: no travel for the patient, a structured shorter session for established cases, and zero premises overhead for you. A well-structured chronic disease management follow-up at ₹600-900 is both fair and sustainable. Pricing below that to compete with platform listings is a race you will lose; pricing at it confidently signals appropriate positioning.

• Register for ABHA and encourage your patients to create health IDs. The Ayushman Bharat Digital Mission infrastructure is building toward national health record interoperability. Early adoption is currently low-cost and low-friction. The practitioners who have integrated ABHA workflows before it becomes operationally pressured will have a measurable advantage in the three-to-five year horizon.

• If you practise psychiatry, clinical psychology, or dermatology - begin this month. These three specialties have the strongest evidence base, the clearest patient preference drivers, and the lowest infrastructure barrier for telemedicine entry. A stable broadband connection, a well-lit consultation room, a consent form, and a booking workflow are sufficient to start. The practitioners who have waited for perfect conditions have mostly not started. Those who started with adequate conditions have, in most cases, built something worth having.

---

Q: My patients keep cancelling telemedicine appointments at the last minute. What am I doing wrong?

Cancellation rates for telemedicine are consistently higher than in-person appointments across all platforms and practice settings - this is well-documented and not specific to your practice. Two mechanisms drive it. First, the commitment cost is lower: no travel time, no parking, no waiting room investment means cancellation feels costless to the patient. Second, many patients cancel because the appointment felt premature when they booked - they were anxious, felt somewhat better by appointment day, and the perceived urgency diminished. Both problems respond to the same intervention: a structured confirmation message sent 24-48 hours before the appointment that restates exactly what will be reviewed and why it is clinically relevant to complete. For chronic disease management appointments specifically, attaching a brief pre-consultation preparation prompt - blood pressure readings from the last two weeks, blood sugar log, current medication list - increases the patient's investment in the appointment and materially reduces cancellation rates. It also improves the quality of the consultation when it does happen.

Q: Can I legally prescribe on a telemedicine consultation in India?

Yes, within specific conditions. The NMC Telemedicine Practice Guidelines permit prescriptions following teleconsultations, subject to the following key constraints: the practitioner must be registered with a State Medical Council; the prescription must carry the practitioner's name, qualification, and registration number; certain drugs - those in Schedule X and others specified in the guidelines - cannot be prescribed through telemedicine without a prior in-person consultation; and follow-up prescriptions for established patients on stable regimens are treated more permissively than new prescriptions for undiagnosed conditions. The guidelines are explicit that telemedicine prescription is not appropriate for conditions that require physical examination to diagnose or monitor safely. Independent practitioners should read the current NMC guidelines directly and not rely solely on platform-specific interpretation, as platform terms may be more permissive than the regulatory standard. Maintaining clear, time-stamped clinical records documenting the basis for each teleconsultation prescription is both a regulatory requirement and a professional protection.

Q: How do I compete with the ₹200 consultations on Practo or 1mg?

The direct answer is: you do not compete with them, because they are not serving the same market. The ₹200 platform consultation is a commodity product for high-volume, low-complexity, low-continuity triage. It attracts patients who want fast answers to minor, self-limiting complaints and who have no intention of building a long-term relationship with a specific practitioner. If that is the segment you are targeting, you will lose that competition - platforms have structural cost advantages you cannot match. Your competitive position as an independent practitioner is continuity, relationship, and clinical judgment built over repeated consultations. The patients worth designing your telemedicine service for are those who value that continuity: patients with chronic conditions who see you quarterly, parents managing a child's long-term asthma or growth concern, patients navigating multi-system complexity. These patients will pay ₹700-1,200 for a structured twenty-minute follow-up with a doctor who knows their full history and does not need the condition re-explained from scratch. They are not the same patients clicking on ₹200 listings. Positioning accordingly means you are not competing - you are operating in a different part of the market entirely.

Q: I tried telemedicine in 2021-22 and it did not work for my practice. Should I try again?

Probably yes, but with a different design. The 2021-22 context was extraordinary: patients were using telemedicine because their other options were closed, which inflated utilisation and obscured underlying fit problems. Practitioners who tried it then often did so without clear use case selection, without a defensible fee structure, and under platform terms that did not reflect their value proposition. Several things are materially different in 2026: the NMC regulatory framework is clearer, patient familiarity with digital consultations is higher, platform integration options are more flexible, and the ABDM infrastructure is more functional. The question is not whether the 2021-22 experience was representative of what telemedicine can deliver for your practice - it likely was not. The question is whether to approach a second attempt with explicit use case selection (start with your chronic disease or mental health follow-up cohort), a clear fee structure, and a defined patient base, rather than opening broadly to platform traffic and accepting whatever comes.

Q: What is the minimum infrastructure I need to start a telemedicine service?

Less than you likely think. A stable broadband connection or 5G, a smartphone or laptop with a front-facing camera, a well-lit room with a reasonably neutral background, a digital consent form, and a booking and payment workflow. The booking workflow can start as simply as a WhatsApp Business account with a Calendly or equivalent link for appointment scheduling. The clinical infrastructure matters more than the technical: a clear written definition of which appointment types you will accept online, a protocol for when to redirect patients to in-person evaluation, and a record-keeping system that documents telemedicine consultations with the clinical detail required for NMC and DPDPA compliance. The practitioners with the most functional independent telemedicine practices started with exactly this infrastructure and built incrementally; those who waited for a purpose-built technical setup typically waited long enough that the momentum was lost. Start with the cases where the fit is clearest, with the patients who trust you most, and iterate from there.

---

Internal - Influx Health Institute

• Digital Presence Fundamentals for Indian Practitioners
• What Patients Find When They Search for You
• AI Diagnostics in India: Where the Evidence Actually Stands

External - Authoritative Sources

• NMC Telemedicine Practice Guidelines (latest revision): https://www.nmc.org.in/information-desk/for-doctors/telemedicine/
• Sharma et al. (2025), "Healthcare utilization patterns among PM-JAY eligible populations across seven Indian states," Global Health Action, PMC11998304: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998304/
• Ayushman Bharat Digital Mission / ABHA health ID registration and documentation: https://abdm.gov.in/

---

Read Next: AI Diagnostics in India: Where the Evidence Actually Stands - the third article in this Center 10 series, examining Niramai, Qure.ai, Tricog, and the clinical and regulatory landscape for AI decision support tools in Indian practice.

Assess Your Practice: Run your Digital Presence Meter - a free scan that shows exactly how your practice appears to patients searching online today, and which specific gaps are costing you patient enquiries.

Chat with Influx Health: Talk to our team - if you are a healthcare organization evaluating a telemedicine strategy or a broader digital patient acquisition program, our team works exclusively with Indian healthcare providers.

--- ---

# Content Derivatives: Center 10, Article 2 - Telemedicine in India

---

Subject line: The ₹200 consultation trap - and what actually works with telemedicine in 2026

---

Dear Dr. [Name],

Telemedicine in India has a problem the industry rarely discusses honestly: the use cases that generate volume for platforms are not always the use cases where telemedicine actually works.

Six years after the pandemic forced mass adoption, the independent practitioners getting the most from telemedicine are not the ones who ran the highest volumes in 2021. They are the ones who figured out - often after a frustrating first attempt - which cases belong on screen and which do not. In our new Institute article, we map what the evidence actually shows, what e-Sanjeevani's 300 million consultations demonstrate (and what they do not), and where independent practitioners are leaving genuine clinical and economic value on the table.

Three findings worth your attention:

The strongest evidence case for telemedicine is chronic disease management combined with mental health teleconsultation and dermatology triage. These are the use cases where research shows telemedicine is equivalent to or better than in-person, where patients often prefer the channel, and where the economics work for the practitioner at a sustainable fee. If you are not offering structured telemedicine specifically for these cases, you are missing the clearest available opportunity in the current landscape.

The DPDPA - the Digital Personal Data Protection Act, 2023 - creates current statutory obligations for any practitioner collecting or processing patient health information digitally. This includes booking forms, WhatsApp clinical communication, and patient management software. Most independent practitioners are not yet compliant. This is not an abstract future risk.

If you tried telemedicine in 2021-22 and found it did not work for your practice, the conditions are meaningfully different in 2026. The question is not whether to revisit it but how to approach it differently - with a specific use case selection, an existing patient base, and a fee structure that reflects your actual value.

We have also published the SCREEN Matrix in the article - a practical fit tool for deciding which consultation types belong online. It runs against your own appointment history in about two hours and will clarify your telemedicine strategy faster than any platform comparison exercise.

Read the full article: [link to article]

Run your free Digital Presence Meter at influx-health.com/dpm - see how your practice appears to patients searching online today, in four minutes.

Warm regards, The Influx Health Institute Research Team

---

Telemedicine in India: Where It Works (and Where It Doesn't) (12-minute read)

The honest evidence on telemedicine in 2026, for practitioners who want clinical and business clarity - not marketing.

What the research supports: 1. Chronic disease management follow-ups (hypertension, diabetes, asthma) - strong evidence, clear patient acceptance, defensible economics. 2. Mental health teleconsultation - outcomes equivalent to in-person for established patients. Privacy preference is real and documented. 3. Dermatology triage via photographs - validated for ruling out serious diagnoses and prioritising in-person care.

Where telemedicine consistently fails: first consultations for undifferentiated serious complaints; anything requiring physical examination; emergency presentations.

The SCREEN Matrix helps you categorise your own consultation types. Run it against your last 100 appointments - takes about two hours.

Key regulatory note: DPDPA 2023 applies now to any practitioner collecting patient data digitally. Most independent practitioners are not yet compliant.

Full article with evidence citations, the SCREEN framework, and an action checklist: [link]

Free digital presence scan: influx-health.com/dpm

---

Six years into mainstream telemedicine adoption in India, the honest assessment is more complicated than the initial enthusiasm suggested - and considerably more useful.

E-Sanjeevani has crossed 300 million consultations. Apollo 247, Practo, and 1mg have built real scale. India crossed 800 million smartphone users in 2024. By every infrastructure metric, the conditions for telemedicine are exceptional. In practice, the independent practitioners getting the most from it are rarely the ones who adopted most eagerly in 2020-21. They are the ones who determined, usually after a difficult first experience, which cases belong on screen - and which absolutely do not.

The research is clearest in three areas: chronic disease management follow-ups (the single largest underexploited telemedicine opportunity for internal medicine and endocrinology practices), mental health teleconsultation (where video equivalence is well-established and patient privacy preference is documented and real), and dermatology triage via photographs (validated for ruling out serious diagnoses). These are strong-fit use cases. First consultations for undifferentiated complaints, anything requiring physical examination, and emergency presentations are not - not because the technology fails, but because those clinical questions require something a screen cannot provide.

The Influx Health Institute has published a new article mapping the full telemedicine landscape for Indian practitioners: what the evidence shows, what the NMC and DPDPA regulatory picture actually requires, what the e-Sanjeevani scale does and does not demonstrate, and a practical fit matrix called the SCREEN Matrix for making better decisions about which cases to take online.

One finding practitioners frequently miss: the Digital Personal Data Protection Act 2023 creates current obligations for any practitioner collecting patient information digitally. Most independent practitioners are not yet compliant. This is a live risk.

If you tried telemedicine in 2021-22 and found it did not work - the conditions in 2026 are meaningfully different. The question is whether to revisit it with a better-designed approach.

Full article in comments, along with the free Digital Presence Meter link.

---

1/ Telemedicine in India: 300M+ e-Sanjeevani consultations. 800M smartphone users. Regulatory framework established. By every infrastructure metric, the conditions are exceptional. The honest evidence is more nuanced. A thread for Indian practitioners.

2/ The strongest telemedicine use case - chronic disease management follow-ups - is also the most underbuilt by independent practitioners. Hypertension check-ins, diabetes review, asthma monitoring: strong evidence, real patient acceptance, defensible economics. Most clinics are not yet systematically doing this.

3/ Mental health teleconsultation shows outcomes equivalent to in-person therapy for established patients (Lancet Psychiatry meta-analysis, 2022 - directionally applicable to India). For many patients, video is not second-best. The privacy of consulting from home is actively preferred for stigmatised conditions.

4/ Dermatology triage via photographs (store-and-forward, asynchronous) is validated internationally for ruling out serious diagnoses and appropriately prioritising in-person care. Independent dermatologists: this is a low-investment, high-value entry point. Image first, video second.

5/ Where telemedicine consistently fails: first consultations for undifferentiated serious complaints. The clinical interview for "fatigue, weight change, a lump the patient has been worried about" depends on physical proximity. Efficiency that costs diagnostic quality is not efficiency.

6/ The DPDPA - Digital Personal Data Protection Act 2023 - creates current obligations for any practitioner collecting patient health data digitally. Booking forms, WhatsApp clinical communication, patient management software: all in scope. Most independent practitioners are not yet compliant.

7/ The ₹200 platform consultation is a commodity product. Independent practitioners who design their telemedicine service to compete on that terrain lose. The patients worth serving want continuity with a doctor who knows their history. They will pay a fair fee for a structured follow-up. That is a different market.

8/ ABDM and ABHA are worth engaging with now, not when they become operationally unavoidable. The national health stack is building toward interoperability. Early adoption is currently low-cost and low-friction. The window for easy entry will not stay open.

9/ The SCREEN Matrix: a practical fit tool for telemedicine decisions. Categorise your last 100 appointments in about two hours. S: Sustained relationship. C: Chronic condition management. R: Reviewable without examination. E: Established prescription renewal. E: Emotional and mental health. N: Navigation and non-emergency triage.

10/ Full article with evidence citations, the SCREEN framework in detail, a six-point action checklist, and five practitioner FAQs: [link] Free digital presence scan - see how patients find your practice online today: influx-health.com/dpm

---

Article published by the Influx Health Institute. Influx Health is a patient acquisition agency for healthcare organizations in India.